**Additional file 1 - Supplementary Table 1.**

Subanalysis of the features at baseline and follow-up of the groups receiving apremilast (APR) in monotherapy vs in combination with synthetic/biological drugs.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Combined** **group****(N=20)** | **Monotherapy group****(N=31)** | **p** |
| **Age, mean (SD) years** | 46.1 (12.6) | 43.8 (13.8) | 0.65 |
| **Sex, men/women, n/n** | 7/13 | 9/22 | 0.68 |
| **Months with Behçet disease before APR, mean (SD)** | 86.1 (82.6) | 81.1 (72.9) | 0.52 |
| **Treatment before APR onset, (%)** Oral glucocorticoids Colchicine NSAIDs Methotrexate Azathioprine Adalimumab Infliximab Tocilizumab Other treatments | 10010053554530302065 | 909740524820133.242 | 0.150.420.380.810.810.410.13**0.049**0.27 |
| **Main clinical symptoms for starting APR, n (%)** Oral ulcers Genital ulcers Oral and genital ulcers | 6 (30)1 (5)13 (65) | 13 (42)1 (3)17 (55) | 0.67 |
| **Prednisone dose at APR onset, median [IQR], mg/d** | 10 [10-20] | 10 [5-20] | 0.87 |
| **Concomitant treatment** Oral glucocorticoids, n (%) Colchicine, n (%) NSAIDs, n (%) Azathioprine, n Methotrexate, n Hydroxychloroquine, n Sulfasalazine, n Dapsone, n Tocilizumab, n Infliximab, n Adalimumab, n | 13 (65)11 (55)5 (25)75411211 | 15 (48)14 (45)10 (32)00000000 | 0.160.380.57 |
| **Follow-up on APR therapy, mean (SD), months** | 9.3 (7.8) | 7.8 (6.3) | 0.31 |
| **Side effects, (%)** Diarrhea Dyspepsia Headache Nausea Abdominal pain Others | 212126.310.510.50 | 232013.333.36.719.4 | 0.850.920.250.070.630.62 |

Results are expressed as mean ± standard deviation (SD), median [interquartile range: IQR] or as number (percentage: %), depending on the variable analyzed.